p53 Review Article

You have free access to this content

TP53 mutations in workers exposed to occupational carcinogens†

  1. Kirsi Vähäkangas*

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10182

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 240–251, March 2003

Additional Information

How to Cite

Vähäkangas, K. (2003), TP53 mutations in workers exposed to occupational carcinogens. Hum. Mutat., 21: 240–251. doi: 10.1002/humu.10182

Author Information

  1. Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland

*Department of Pharmacology and Toxicology, University of Kuopio, POB 1627, FIN-70211 Kuopio, Finland

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (169K)

REFERENCES

  • Aguilar F, Hussain P, Cerutti P. 1993. Aflatoxin B1 induces the transversion of G – T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 90:8586–8590.
  • Aguilar H, Harris CC, Sun T, Hollstein M, Cerutti P. 1994. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264:1317–1319.
  • Alavanja MCR, Brownson RC, Lubin JH, Berger E, Chang J, Boice JD Jr. 1994.Residential radon exposure and lung cancer among nonsmoking women. JNCI 86:1829–1837.
  • Auvinen A, Mäkeläinen I, Hakama M, Castrén O, Pukkala E, Reisbacka H, Rytömaa T. 1996. Indoor radon exposure and risk of lung cancer: a nested case-control study in Finland. JCNI 88:966.
  • Band PR, Spinelli JJ, Gallagher RP, Threlfall WJ, Ng VT, Moody J, Raynor D, Svirchev LM, Kan D, Wong M. 1990. Identification of occupational cancer risks using a population-based cancer registry. Recent Results Cancer Res 120:106–121.
  • Barbin A, Froment O, Boivin S, Marion MJ, Belpoggi F, Maltoni C, Montesano R. 1997. p53 mutation pattern in rat liver tumors induced by vinyl chloride. Cancer Res 57:1695–1698.
  • Barbin A. 2000. Etheno-adduct-forming chemicals: from mutagenicity testing to tumor mutation spectra. Mutat Res 462:55–69.
  • Bargonetti J, Manfredi JJ. 2002. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14:86–91.
  • Bartsch H, Hollstein M, Mustonen R, Schmid J, Spiethoff A, Wesch H, Wiethege T, Muller KM. 1995. Screening for putative radon-specific p53 mutation hotspot in German uranium miners. Lancet 346:121.
  • Bennett WP, Hussain SP, Vähäkangas KH, Khan MA, Shields PG, Harris CC. 1999. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187:8–18.
    Direct Link:
  • Bernstein C, Bernstein H, Payne CM, Garewal H. 2002. DNA repair/pro-apoptotic dual-role rpoetins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511:145–178.
  • Beroud C, Soussi T. 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176–181.
    Direct Link:
  • Bjelogrlic NM, Mäkinen M, Stenbäck F, Vähäkangas K. 1994. Benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin. Carcinogenesis 15:771–774.
  • Blons H, Laurent-Puig P. 2003. TP53 and head and neck neoplasms. Hum Mutat 21:252–257.
    Direct Link:
  • Bodak N, Queille S, Avril MF, Bouadjar B, Drougard C, Sarasin A, Daya-Grosjean L. 1999. High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum. Proc Natl Acad Sci USA 96:5117–5122.
  • Bonsing BA, Corver WE, Corsica MCB, van Vliet M, Oud PS, Cornelisse CJ, Fleuren GJ. 1997. Specificity of seven moboclonal antibodies against p53 immunohistochemistry, confocal laser scanning microscopy and flow cytometry. Cytometry 28:11–24.
    Direct Link:
  • Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. 1991. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124–10128.
  • Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ. 1995. Association between cigarette smoking and mutation of the p53 gene in squamous cell-carcinoma of the head and neck. N Engl J Med 332:712–717.
  • Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature 350:429–431.
  • Brooks AL, Bao S, Harwood PW, Wood BH, Chrisler WB, Khan MA, Gies RA, Cross FT. 1997. Induction of micronuclei in respiratory tract following radon inhalation. Int J Radiat Biol 72:485–495.
  • Carbone M, Kratzke RA, Testa JR. 2002. The pathogenesis of mesothelioma. Semin Oncol 29:2–17.
  • Castren K, Ranki A, Welsh JA, Vähäkangas KH. 1998. Infrequent p53 mutations in arsenic-related skin lesions. Oncol Res 10:475–482.
  • Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, et al. 1990. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung cancer study group. Oncogene 5:1603–1610.
  • Chuang JC,Wise SA, Cao S, Mumford JL. 1992. Chemical characterization of mutagenic fractions of particles from indoor coal combustion: a study of lung cancer in Xuan Wei, China. Environ Sci Technol 26:999–1004.
  • Colman MS, Afshari CA, Barrett JC. 2000. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 462:179–188.
  • Cross FT. 1994. Invited commentary: residential radon risks from the perspective of experimental animal studies. Am J Epidemiol 140:333–339.
  • Dare E, Tofighi R, Vettori MV, Momoi T, Poli D, Saido TC, Mutti A, Ceccatelli S. 2002. Styrene 7,8-oxide induces caspase activation and regular DNA fragmentation in neuronal cells. Brain Res 933:12–22.
  • Davenport V, Morris JF, Motazed R, Chu AC. 1999. p53 induction in normal human skin in vitro following exposure to solar simulated UV and UV-B irradiation. J Photochem Photobiol 49:177–186.
  • Daya-Grosjean L, Dumaz N, Sarasin A. 1995. The specificity of p53 mutation spectra in sunlight inducedhuman cancers. J Photochem Photobiol B 28:115–124.
  • DeMarini DM, Landi S, Tian D, Hanley NM, Li X, Hu F, Roop BC, Mass MJ, Keohavong P, Gao W, Olivier M, Hainaut P, Mumford JL. 2001. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. Cancer Res 61:6679–6681.
  • Denissenko MF, Pao A, Tang M, Pfeifer GP. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274:430–432.
  • Dennissenko MF, Koudriakova TB, Smith L, O'Connor TR, Riggs AD, Pfeifer G. 1998. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistemce of aflatoxin B1 adducts. Oncogene 17:3007–3014.
  • Dumaz N, Stary A, Soussi T, Dayagrosjean L, SarasinA. 1994. Can we predict solar ultraviolet radiation as the causal event in human tumors by analysing the mutation spectra of the p53 gene. Mutat Res 307:375–386.
  • Esteve A, Sorlie T, Martel-Planche G, Hollstein M, Kusters I, Lewalter J, Vineis P, Stephan-Odenthal M, Montesano R. 1995. Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med 37:59–68.
  • Fisher DE. 2001. The p53 tumor suppressor: critical regulator of life and death in cancer. Apoptosis 6:7–15.
  • Fujimoto Y, Hampton LL, Luo L-d, Wirth PJ, Thorgeirsson SS. 1992. Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in non-human primates. Cancer Res 52:1044–1046.
  • Giglia-Mari G, Sarasin A. 2003. TP53 mutations in human skin cancers. Hum Mutat 21:217–228.
    Direct Link:
  • Gloster HM, Jr., Brodland DG. 1996. The epidemiology of skin cancer. Dermatol Surg 22:217–226.
  • Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878.
  • Hackshaw AK, Law MR, Wald NJ. 1997. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 315:980–988.
  • Hainaut P, Vähäkangas K. 1997. p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol (Paris) 45:833–844.
  • Hainaut P, Hollstein M. 2000. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81–137.
  • Hainaut P, Pfeifer GP. 2001. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22:367–374.
  • Hanaoka T, Yamano Y, Katsuno N, Kagawa J, Ishizu S. 1997. Elevated serum levels of pantropic p53 proteins in chromium workers. Scand J Work Environ Health 23:37–40.
  • Harris CC. 1991. Chemical and physical carcinogenesis: advances and perspectives for the 1990's. Cancer Res 51:5023s–5044s.
  • Harty LC, Guinee Travis WD Jr, Bennett WP, Jett J, Colby TV, Tazelaar H, Trastek V, Pairolero P, Liotta LA, Harris CC, Caporaso NE. 1996. p53 mutations and oocupational exposures in a surgical series of lung cancers. Cancer Epidemiol Biomarkers Prev 5:997–1003.
  • Hei TK, Wu L-J, Liu S-X, Vannais D, Waldren CA, Randers-Pehrson G. 1997. Mutagenic effects of a single and an exact number of α-particles in mammalian cells. Proc Natl Acad Sci USA 94:3765–3770.
  • Hickman AW, Jaramillo RJ, Lechner JF, Johnson NF. 1994. Alpha-particle-induced p53 protein expression in a rat lung epithelial cell strain. Cancer Res 54:5797–5800.
  • Hirose T, Kondo K, Takahashi Y, Ishikura H, Fujino H, Tsuyuguchi M, Hashimoto M, Yokose T, Mukai K, Kodama T, Monden Y. 2002. Frequent microsatellite instability in lung cancer from chromate-exposed workers. Mol Carcinog 33:172–180.
    Direct Link:
  • Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49–53.
  • Hollstein M, Marion MJ, Lehman T, Welsh J, Harris CC, Martel-Planche G, Kusters I, Montesano R. 1994. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 15:1–3.
  • Hollstein M, Bartsch H, Wesch H, Kure EH, Mustonen R, Mühlbauer K-R, Spiethoff A, Wegner K, Wiethege T, Müller K-M. 1997. P53 gene mutation analysis in tumors of patients exposed to α-particles. Carcinogenesis 18:511–516.
  • Hsieh LL, Chen HJ, Hsieh JT, Jee SH, Chen GS, Chen CJ. 1994. Arsenic-related Bowen's disease and paraquat-related skin cancerous lesions show no detectable ras and p53 gene alterations. Cancer Lett 86:59–65.
  • Hsu CH, Yang SA, Wang JY, Yu HS, Lin SR. 1999. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer 80:1080–1086.
  • Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427–428.
  • Husgafvel-Pursiainen K, Kannio A, Oksa P, Suitiala T, Koskinen H, Partanen R, Hemminki K, Smith S, Rosenstock-Leibu R, Brandt-Rauf PW. 1997. Mutations, tissue accumulation, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutag 30:224–230.
    Direct Link:
  • Husgafvel-Pursiainen K, Karjalainen A, Kannio A, Anttila S, Partanen T, Ojajärvi A, Vainio H. 1999. Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations. Am J Respir Cell Mol Biol 20:667–674.
  • Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G, Mukeria A, Constantinescu V, Fortes C, Benhamou S. 2000. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res 60:2906–2911.
  • Hussain SP, Kennedy CH, Amstad P, Lui H, Lechner JF, Harris CC. 1997. Radon and lung carcinogenesis: mutability of p53 codons 249 and 250 to 238Pu α-particles in human bronchial epithelial cells. Carcinogenesis 18:121–125.
  • IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to man. 1980. Some metals and metallic compounds. IARC Monogr Eval Carcinog Risk Chem Hum 23.
  • IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to man. 1983. Polynuclear aromatic compounds, Part 1: chemical, environmental and experimental data. IARC Monogr Eval Carcinog Risk Chem Hum 32.
  • IARC. onographs on the evaluation of the carcinogenic risk of chemicals to man. 1986. Tobacco smoking. IARC Monogr Eval Carcinog Risk Chem Hum 38:35–394.
  • IARC. onographs on the evaluation of the carcinogenic risk of chemicals to man. 1988. Man-made mineral fibres and radon. IARC Monogr Eval Carcinog Risk Chem Hum 43:173–259.
  • Jostes RF. 1996. Genetic, cytogenetic, and carcinogenic effects of radon: a review. Mutat Res 340:125–139.
  • Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. 1992. p53 expression is common in malignant mesothelioma. Histopathology 21:331–334.
    Direct Link:
  • Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311.
  • Kielhorn J, Melber C, Wahnschaffe U, Aitio A, Mangelsdorf I. 2000. Vinyl chloride: still a cause for concern. Environ Health Perspect 108:579–588.
  • Kirby GM, Batist G, Fotouhi-Arkadani N, Nakazawa H, Yamasaki H, Kew M, Cameron RG, Alaoui-Jamali MA. 1996. Allele-specific PCR analysis of p53 codon 249 AGT transversion in liver tossues from patients with viral hepatitis. Int J Cancer 68:21–25.
    Direct Link:
  • Kitamura F, Araki S, Tanigawa T, Miura H, Akabane H, Iwasaki R. 1998. Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos: PCR-SSCP and sequencing analyses of paraffin-embedded promary tumors. Ind Health 36:52–56.
  • Kitamura F, Araki S, Suzuki Y, Yokoyama K, Tanigawa T, Iwasaki R. 2002. Assessment of the mutations of p53 tumor suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. Ind Health 40:175–181.
  • Kondo K, Hino N, Sasa M, Kamamura Y, Sakiyama S, Tsuyuguchi M, Hashimoto M, Uyama T, Monden Y. 1997. Mutations of the p53 gene in human lung cancer from chromate-exposed workers. Biochem Biophys Res Commun 239:95–100.
  • Kropveld A, Rozemuller EH, Leppers FG, Scheidel KC, de Weger RA, Koole R, Hordijk GJ, Slootweg PJ, Tilanus MG. 1999. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 79:347–353.
  • Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, Van Broeckhoven C, Van Marck E. 1997. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 181:67–74.
    Direct Link:
  • Laffon B, Pasaro E, Mendez J. 2001. Effects of styrene-7,8-oxide over p53, p21, bcl-2 and bax expression in human lymphocyte cultures. Mutagenesis 16:127–132.
  • Lan Q, He X, Costa DJ, Tian L, Rothman N, Hu G, Mumford JL. 2000. Indoor coal combustion emissions, GSTM1 and GSTT1 genotypes, and lung cancer risk: a case-control study in Xuan Wei, China. Cancer Epidemiol Biomarkers Prev 9:605–608.
  • Lane DP. 1992. p53, guardian of the genome. Nature 358:15–16.
  • Lehnert BE, Goodwin EH. 1997a. A new mechanism for DNA alterations induced by alpha particles such as those emitted by radon and radon progeny. Environ Health Perspect 105:1095–1101.
  • Lehnert BE, Goodwin EH. 1997b. Extracellular factor(s) following exposure to α-particles can cause sister chromatid exchanges in normal human cells. Cancer Res 57:2164–2171.
  • Little JB. 1998. Radiation-induced genomic instability. Int J Radiat Biol 74:663–671.
  • Lo YMD, Darby S, Noakes L, Whitley E, Silcocks PBS, Fleming KA, Bell JI. 1995. The Lancet 345:60.
  • Lubin JH, Boice JD Jr. 1997. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. JNCI 89:49–57.
  • Luo JC, Liu HT, Cheng TJ, Du CL, Wang JD. 1999. Plasma p53 protein and anti-p53 antibody expression in vinyl chloride monomer workers in Taiwan. J Occup Environ Med 41:521–526.
  • Mantovani F, Banks L. 2001. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20:7874–7887.
  • Marion MJ. 1998. Critical genes as early warning signs: example of vinyl chloride. Toxicol Lett 102–103:603–607.
  • Mayal FG, Jacobson G, Wilkins R. 1999. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. J Clin Pathol 52:291–293.
  • McDonald JW, Taylor JA, Watson MA, Saccomanno G, Devereux TR. 1995. p53 and K-ras in radon associated lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 4:791–793.
  • Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI, et al. 1992. P53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52:2610–2615.
  • Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J. 1998. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 78:1084–1090.
  • Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F, Rechavi G, Reichert N. 1997. Absence of p53 mutations in malignant mesothelioma. Am J Respir Cell Mol Biol 16:9–13.
  • Mumford JL, Helmes CT, Lee XM, Seidenberg J, Nesnow S. 1990. Mouse skin tumorigenicity studies of indoor coal and wood combustion emissions from homes of residents in Xuan Wei, China with high lung cancer mortality. Carcinogenesis 11:397–403.
  • Nair U, Bartsch H. 2001. Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer. IARC Sci Publi 154:271–290.
  • Nakanishi Y, Chen S, Inutsuka S, Ma Y, Jiang X, Hara N, Sera N, Tokiwa H. 1997. Possible role of indoor environment and coal combustion emission in lung carcainogenesis in Fuyuan county, China. Neoplasma 44:69–72.
  • Ng IOL, Srivastava G, Chung LP, Tsang SWY, Ng MMT. 1994. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer 74:30–37.
    Direct Link:
  • Ni Z, Liu Y, Keshava N, Zhou G, Whong W, Ong T. 2000. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 468:87–92.
  • Nickels A, Selter H, Pfreundschuch M, Montenarh M, Koch B. 1997. Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment. J Clin Pathol 50:654–660.
  • Nuorva K, Mäkitaro R, Huhti E, Kamel D, Vähäkangas K, Bloigu R, Soini Y, Pääkkö P. 1994. p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J Respir Crit Care Med 150:528–533.
  • Ogretmen B, Safa AR. 1997. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 14:499–506.
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614.
    Direct Link:
  • Ozturk M. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338:1356–1359.
  • Pershagen G, Åkerblom G, Axelson O, Clavensjo B, Damber L, Desai G, Enflo A, Lagarde F, Mellander H, Svartengren M, et al. 1994. Residential radon exposure and lung cancer in Sweden. N Engl J Med 330:159–164.
  • Pfeifer GP, Denissenko MF. 1998. Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations? Environ Mol Mutagen 31:197–205.
    Direct Link:
  • Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainut P. 2002. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435–7451.
  • Ponten F, Lindman H, Bostrom A, Berne B, Bergh J. 2001. Induction of p53 expression in skin by radiotherapy and UV radiation: a randomized study. J Natl Cancer Inst 93:128–133.
  • Puisieux A, Lim S, Groopman J, Ozturk M. 1991. Selective targeting of p53 gene mutational hotspots in humancancers by etiologically defined carcinogens. Cancer Res 51:6185–6189.
  • Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W, van Marck E. 1992. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168:371–375.
    Direct Link:
  • Rämet M, Castrén K, Järvinen K, Pekkala K, Turpeenniemi-Hujanen T, Soini Y, Pääkkö P, Vähäkangas K. 1995. p53 protein expression is correlated with benzo(a)pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 16:2117–2124.
  • Rössner P, Binkova B, Chvatalova II, Sram RJ. 2002. Acrylonitrile exposure: the effect on p53 and p21(WAF1) protein levels in the blood plasma of occupationally exposed workers and in vitro in human diploid lung fibroblasts. Mutat Res 517:239–250.
  • Roth S, Partanen T, Suitiala T, Anttila S, Ojajarvi A, Hemminki K, Vainio H, Husgafvel-Pursiainen K. 1997. Molecular analysis of occupational cancer: infrequent p53 and ras mutations in renal-cell cancer in workers exposed to gasoline. Int J Cancer 73:492–496.
    Direct Link:
  • Scorsone KA, Zhou Y-Z, Butel JS, Slagle BL. 1992. P53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 52:1635–1638.
  • Segers K, Backhovens H, Singh SK, De Voecht J, Ramael M, Van Broeckhoven C, Van Marck E. 1995. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Virchows Arch 427:431–436.
  • Serpi R, Piispala J, Järvilehto M, Vähäkangas K. 1999. Thapsigargin has similar effect on p53 protein response to benzo(a)pyrene-DNA adducts as TPA in mouse skin. Carcinogenesis 20:1755–1760.
  • Shibata A, Ohneseit PF, Tsai YC, Spruk CH, 3rd, Nichols PW, Chiang HS, Lai MK, Jones PA. 1994. Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15:1085–1087.
  • Slebos RJC, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, Bracci PM, Foley J, Stockton P, McGregor LM, Flake GP, Taylor JA. 2000. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biom Prev 9:1223–1232.
  • Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP. 2000. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 92:803–811.
  • Smith SJ, Li Y, Whitley R, Marion MJ, Partilo S, Carney WP, Brandt-Rauf PW. 1998. Molecular epidemiology of p53 protein mutations in workers exposed to vinyl chloride. Am J Epidemiol 147:302–308.
  • Soini Y, Welsh JA, Ishak KG, Bennett WP. 1995. p53 mutations in primary hepatic engiosarcomas not associated with vinyl chloride exposure. Carcinogenesis 16:2879–2881.
  • Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey. 1992. Frequent p53 mutations in head and neck cancer. Cancer Res 52:5997–6000.
  • Sorlie T, Martel-Planche G, Hainaut P, Lewalter J, Holm R, Borresen-Dale AL, Montesano R. 1998. Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumors from workers exposed to aromatic amines. Br J Cancer 77:1573–1579.
  • Soussi T. 2000a. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910:121–137.
    Direct Link:
  • Soussi T. 2000b. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788.
  • Soussi T, Dehouche K, Beroud C. 2000. P53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15:105–113.
    Direct Link:
  • Staib F, Hussain SP, Wang XW, Harris CC. 2003. TP53 and liver carcinogenesis. Hum Mutat 21:201–216.
    Direct Link:
  • Takeshima Y, Inai K, Bennett WP, Metcalf RA, Welsh JA, Yonehara S, Hayashi Y, Fujihara M, Yamakido M, Akiyama M, et al. 1994. p53 mutations in lung cancers from Japanese mustard gas workers. Carcinogenesis 15:2075–2079.
  • Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M. 1994. Mutational hotspot in the p53 gene in radon-associated lung tumors from uranium miners. Lancet 343:86–87.
  • Taylor JA, Li Y, He M, Mason T, Mettlin C, Vogler WJ, Maygarden S, Liu E. 1996. p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res 56:294–298.
  • Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S. 1994. P53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 54:231–235.
  • Toyooka S, Tsuda T, Gazdar AF. 2003. The TP53 gene, tobacco exposure and lung cancer. Hum Mutat 21:229–239.
    Direct Link:
  • Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC, Harris CC. 1995. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87:1400–1407.
  • Turpeinen M, Serpi R, Rahkolin M, Vähäkangas K. 2002. Comparison of anti-p53 antibodies in immunoblotting. Biochem Biophys Res Commun 293:850–856.
  • Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, Harris CC. 1992. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339:576–580.
  • Vähäkangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, Alavanja MC, Harris CC. 2001. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 61:4350–4356.
  • Vähäkangas KH. 2002. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. In: DriscollB, editor. Methods in molecular medicine, vol 47. Lung cancer, vol 1. Molecular pathology methods and reviews. Totowa, NJ: Humana Press Inc. p 43–59.
  • Venitt S, Biggs PJ. 1994. Radon. Mycotoxins, p53 and uranium mining. Lancet 343:795.
  • Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307–310.
  • Wang XW, Hussain XP, Huo TI, Wu CG, Forgues M, Hofset LJ, Brechot C, Harris CC. 2002. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181–182:43–47.
  • Wei M, Wanibuchi H, Morimura K, Iwai S, Yoshida K, Endo G, Nakae D, Fukushima S. 2002. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 23:1387–1397.
  • Weihrauch M, Lehnert G, Kockerling F, Wittekind C, Tannapfel A. 2000. p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride. Cancer 88:1030–1036.
    Direct Link:
  • Weihrauch M, Bader M, Lehnert G, Wittekind C, Tannapfel A, Wrbitzky R. 2002. Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV radiation-induced basal cell carcinoma. Int Arch Occup Environ Health 75:272–276.
  • Wong RH, Du CL, Wang JD, Chan CC, Luo JC, Cheng TJ. 2002. XRCC1 and CYP2E1 polymorphisms assusceptibility factors of plasma mutant p53 protein and anti-p53 antibody expression in vinyl chloride monomer-exposed polyvinyl chloride workers. Cancer Epidemiol Biomarkers Prev 11:475–482.
  • Yang Q, Wesch H, Mueller K-M, Bartsch H, Wegener K, Hollstein M. 2000. Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hotspot mutation. Br J Cancer 82:763–766.
  • Yasunaga Y, Nakanishi H, Naka N, Miki T, Tsujimura T, Itatani H, Okuyama A, Aozasa K. 1997. Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. Lab Invest 77:677–684.
  • Yih L-H, Lee T-C. 2000. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res 60:6346–6352.
  • Yngveson A, Williams C, Hjerpe A, Lundeberg J, Soderkvist P, Pershagen G. 1999. p53 Mutations in lung cancer associated with residential radon exposure. Cancer Epidemiol Biomarkers Prev 8:433–438.
  • Zhang ZF, Sarkis AS, Cordon-Cardo C, Dalbagni G, Melamed J, Aprikian A, Pollack D, Sheinfeld J, Herr HW, Fair WR, et al. 1994. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 3:19–24.
Get PDF (169K)